FSTX - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the F-star Therapeutics, Incorporated Second Quarter 2021 Earnings Call and Corporate Update. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session, and instructions will follow at that time.

conference recorded this replay. available reminder, a will and be for As would you for Investor introduce like F-star. Lindsey I to of to now Trickett, VP Relations Please go ahead.

Lindsey Trickett

me you Hi, Deptula-Hicks, Darlene quarter We pre-market joining everyone. ending good results CFO. Eliot Thank financial for and us. CEO; morning, our With today today announced and June is Forster, XXXX. for the XX,

website on at the access Relations Investor can the press release F-star.com. of You our page

or forward-looking materially that These therefore detailed and that no statements you to could cause the note company a The any events filings a number are Before be order our and guarantees started, it and forward-looking that on that our we subject obligation today, undue call. uncertainties part results of actual to that, hand reliance let's statements through that may date risks undertakes in of this discussion statements to them. Please anticipated. get of Such from Investors are not to run performance, constitute statements making not quickly With statements. forward-looking also historical I'll cautioned reflect after are differ future conference and the as management SEC. should will statements. include ahead, Go forward-looking risks, Eliot. Eliot. those over of arise with These F-star's to are update strictly the place statements. forward-looking circumstances uncertainties not risks

Eliot Forster

seven financing we few second been we quarter provide past the months. ensures of quarter This in gross corporate have milestones, group includes to with and future speak our financial positive over Thanks investors. position which a I'll strength a of further F-star in now is top Lindsay. facility. and updates completed underwritten million great aftermarket highlight Welcome what's on you delivery We everyone XXXX tier offering that the The earnings It's raised second research that now and call. proceeds the to equity analysts and today. institutional of $XX update today another the covering public the between clinical

clinical LAG-X of It's On activities. exciting you for PDL-X as progress an with with well we're and FSXXX today the bispecific or the that the trials. patients, pleased an naive strategy FSXXX say antibody of development extremely and share as patients more clinical I'll through for to opportunity FSXXX addition the updated checkpoint clinical the side, first shortly. to continue to in-human F-star, on

at a with MSD You may We're FSXXX have Keytruda making announced collaboration for partnership this the U.S. we In and as outside Merck year's FSXXX plan be program keeping combo sharing initiate of this have we'll news to known with next on for seen updates meeting. combining FSXXX excited ESMO year. the our conferences, last agreement that week at trial Keytruda. to completed with preference

the month. we've quarter, development We gave on STING AstraZeneca both XXXXX the this our Antagonist, reported agonist our significant to licensed STING and During preclinical inhibitor for progress a clinical the in inhibitor. of programs, future and just STING and commercialization, SB the past update with

of I bit I'll partnerships the to partners delighted a our long the collaborations. with granted four X, On our to then our standing look XXXXX work fruitful underway, that Denali you we further And SB you review now continues clinical patent a Slide through upcoming that patent forward KGaA, additional During We've quarter, have we and and of can Darmstadt. and to-date AstraZeneca. Merck detail and new and the been USA. the with stage these more partner in now on programs XXXX we're composition continue milestones. programs, positive our of of patent see also matter provide pipeline, This protecting without extensions. remind each

Here Slide X. on

You'll resistant half Phase the cancers. see with and X ongoing trial proof-of-concept We being neck in in of PD-X XXXX. patients FSXXX in that this head first study is studied anticipate an currently reporting on

expanding few addition, population, low and on to this we're patient patients further into with outcomes is inhibitor, high provide checkpoint FSXXX in the unmet significantly slides. I'll with area details for improve medical naive In an tumors, designed PD-LX coming need. a

phase, effector, earlier wider a XXXXX disease This and on in cohorts combination This this generation is safe pleased cause affinities relative clinical of that expansion target is them FSXXX and and not that to the trial CDXXX in a as pharmacologically driven SB half the remember with combination opportunities curve You'll dose tolerated the self-compete. stabilization. seeking the upcoming we're at we've to In uptake. into do in the Tecentriq to or with going Phase program. drugs first signs and avoids observe well point with Keytruda. more targeting encouraged trigger of continue seen progress for as as determine the provide we'll in-human early that Meanwhile, we'll us providing currently the PD-LX. each which monotherapy. as to We second delivered in I in uniquely can dose year. anticipate drug. to rapid update hook study, binding and mentioned additional explore active additional form ongoing such the monotherapy, or to to STING for promising bell-shaped detailed systemically, the dose strategic has This Agonists biomarker We're the of a Again, other of continue X engineered, with be cellular trials the conference. ESMO FSXXX, benefit first ascending next to a information at this

the to you expansion development on give some detail the to Moving clinical I'm FSXXX X, of of activities. Slide pleased

wide in patients resistance saw specific the X of particular and options available You proof-of-concept on patients study and therefore might neck in that heavily Based pretreated This them these the population. data, in of a X PD-LX with a we remember acquired cohort represent positive from Phase trial patients, patients in with patient expression whole data have LAG-X. acquired ongoing group therapeutic and head the we Phase subgroup of few resistance to initiated of cancer.

to we that here success anticipated, progress gain a past provide conference PD-LX numbers on first to data to be field with our non-small large therapy. in lead can we'll X LAG-X Despite the be clinical additional of coupled that XXXX progress This to are a lung preclinical of own of with plan way target this see Like in significant FSXXX. a lasting area. proof-of-concept therapy. huge marked a naive happy not in year. with all this the Phase two for did pivotal immune half However, significant oncology anticipate and trial checkpoint to the in a a later are in the checkpoint PD-X we opportunity firm both of of And to was LAG-X in emerge trial third as FSXXX. we external this The inhibitor milestone ASCO the oncology. a an And will the diffused patients a market that community update cancer faster validation and advances or large of validation the immuno-oncology we important LAG-X of patients believer continue potential trial delighted starting cell see to who for for recent The and been our through be biomarker study. inhibitor We've starting whole it option real the represents. The cell melanoma. means will and long clinical patients clinical as the B in programs, decades, this lymphoma benefits pathway believe remains enriched, we of from

greater are but resistance also of first to that not a potentially options checkpoint of cancers, quality of both control life. inhibitors, disease in provide We treatment fully the terms transform patients their committed avoid generation treatment advanced only the of but to with experience and

data. led treatments. next always a to our be continue X looking before immune hand bring additional I reminder And oncology Slide ways months be of XX We for F-star. to to patients for with is benefits We'll the Darlene, what generation of the hold to over next by

We expect and on year, share data four on see Later scientific which progress you'll across medical highlighting our will multiple FSXXX. or FSXXX, clinical data readouts, programs. conferences this

data Next that you on population, of and FSXXX XXXXX updates the SB its to share on FSXXX. and show acquired continued clinical year, further give resistance patient progress plan we and trial

medicines for as move tetravalent, Also I'll combination As our the I'm very this on the tirelessly investors that, for a life with believe our our towards we who, with platform bispecific progress forward programs to are create hand transform the you with from existing discovery give Darlene? cancer. to update as bringing I F-star of to the have And patients into and who our look the well us we grateful KEYTRUDA. upcoming and future. to near lives on support value in with new and employees efforts clinic a for our progress future changing financials. you milestones We over based journey an on work sharing of Darlene these to at additional with shareholders. technology. bright

Darlene Deptula-Hicks

Eliot Thanks, morning, and good everyone.

the for million, top tier with solid development now of for at and As million of Eliot equivalents second offering We're were $XX.X QX, highlighted, plan combined which a June quarter and clinical $XX.X Cash and and company's through $XX.X including extremely FSXXX in for ATM of a our expanded I'll to the be from from go results provides XX, common the real a joined million program and and company. take offering for financial clinical netted strategy, happy stock investors the that the have questions which after equity as on of executing financial outlined, equity end. just quarter proceeds expenses. our our pleased progress it's recent been we'll fees cash platform financing XXXX us. the who public successful the Elliot resulting XXXX,

plan, a that the facility entered also across of plan us QX second including down out multiple about cash half FSXXX, call, for and clinical $XX we believe of of projected into milestones of our amount earlier our well full in We delivery debt operating million be of laid plan, operating programs. development to the a cash runway continues our on cost the the including Eliot to drew our facility. quarter expanded a to will XXXX. four current earnings our all clinical In by sufficient guided QX believe current fund into runway. cash We We

the Denali. to Merck to period Currently, and revenue due transition to reduction with compared and revenue, of for a as arrangements now quarter to not the $XXX,XXX This have development partner XXXX in research ended zero do revenue this our was with partners the XX, as an consistent phase, same expected, services is now and phase June to $XXX,XXX development with we all decrease primarily strategy. milestone the XXXX. end either for have as Turning is and ongoing programs service and research any research collaboration come have in

million compared of increase includes a as our million related reminder, million $X or million CRO $X.X quarter second million incentive four XXXX. increase costs, comparable XX, $X.X were the the XXXX. million R&D to research in $X and in to to is quarter. for the option due legal million respectively. An that expenses the XXXX, ended time and/or comparative $X.X a increase an another manufacturing development clinical to and costs. clinical tax a Total XXXX our June stage then $X.X primarily in to XXXX This compared QX, to quarter million platform prior and is interest in conversation continue non-cash general public development $X.X programs $X.X exercise $X development compared A $X.X the stock-based of quarter decrease and in quarter milestone million diluted expenses second million $X.XX being typically associated quarter compensation for with XXXX quarter $X.X As year amounts per for well administrative XXXX. were of in $X.X upfront grow stock-based in compared about including of and credit in - G&A the resulting the fees, quarter amounts $X.X quarter, second over F-star expense per for share-based net U.K. increase our of expense This XXXX quarter share XXXX G&A for was with costs in revenue costs. million increase the second for Net XXXX. from expense, the general included relate costs share, manufacturing research seen for batch diluted costs $X.X having QX, services. community. million primarily respectively. as of $X.X million XXXX a expense $X.X this our we've expenses clinical Total million in other non-cash our $X.X compensation R&D due million $XX.X payments, and to also and second clinical basic investment the as professional historically basic of and and one closing million in $X.X of and research or of insurance million project other this of include compensation of and loss due million with million and an to over related payments, for in and $XXX,XXX In loss positive $X.XX payments, program bispecific second company past quarter, $X.X clinical as programs, assay and million increase compensation and of

equity covered questions. financial our all delivery are position of company. we're milestones the by we'll seven and analysts the will believe four clinical their encouraged course With up you our Additionally, of call solid of supports we across thank by of open financial the for continue now management programs, and We and research ensure that, effective now to all multiple engagement.

Operator

Your Leerink. first Daina for is of question SVB Instructions] with the line [Operator Graybosch

Daina Graybosch

biologic varies on, second Good me for cell trial? cancer morning. Good if to you across wonder whether now speak types. suites data proof-of-concept belief the selecting that are on which you afternoon. related. diffuse is lymphoma dominating LAG-X and most rationale current ligand relevant? the are lung do And new this the large pursuing then I the Maybe your and B-cell any is two cancer the tumor non-small could for FSXXX And question ligand and for have types what, is you're studies which One,

Eliot Forster

the for Thanks questions.

number our underlying non-small and both Clearly occasions, a to that the revealing those lung later. which that B-cell with that around that hypothesis of cell be I've we and - But I to and that PD-LX. disease discussed provide externally that it's superior to own say the give cancer fair those to co-expression some you cause only patients will and data us have of of of settings course, believe co-expression. a both Of LAG-X some we related in benefits think observed lymphoma, on can settings we've in details of because

interesting more and a to it's on that. appear it's and coming With to case more respect ligands, more that details So along. be ligands LAG-X/PD-LX, later co-expression the kind of

you surface recall actually As that mechanism for dominant exhausted may us, is cells. those of our LAG-X cleavage the immune from

mechanism we not the caused ligand you not So it, is the has it's course, else irrelevant. of it's one extent, sure published although that no receptor at because plus know so totally unique, of can't if rare, - to we but And least unique mechanism provide in be through our its and first instance, some shedding interaction two that bispecifics. we LAG-X as two the with

Operator

Matt of with line from William is the question Phipps Next Blair.

Matt Phipps

though, well to it questions obviously or the glad there? that you guess and trial some I is trial crowded data. you expansion first point think after there this and co-expression of any in poster? pretty Bristol updates to see taking data kind niche that you can then, much, biomarker but I from as there and of Is some definitely progress I Yes, other come when entrench out up population And my they’re too say progress lung have regimen. don't I one some carve high here was to poster. say kind that PD-LX population really saw in with the thanks the XXX space pure cancer, maybe patient differs a or think just for maybe maybe real Do and

Eliot Forster

to Sure, hey I'm talk Good morning. to the analysts to this Matt pleased and And all again. be talking nice so to morning.

an will Opdivo knock rollout update. to information whole respect stay just in you imagine, lung try begin are LAG-X - And their respect to co-expression, to not now, Keytruda with cancer for see PD-LX groups the and patient With and how trial as us within population. with co-expressing that certainly going or I'll believe off lung in over spots lung So We've might in cancer progress of emerging. to year we seen kind start thing ESMO, that is is it of rest advantage the of through cancer thinking. give you'll this a to FSXXX cell some that will non-small we design, trial the

have clear as agreement. What is I on. And and us materials biological know in allowed for to questions combination. Keytruda a escalation the activity I agonist. to biology make think, confidence first-in-class of looking as we early and underlying that, we've the signs ESMO, think confines MSD, some at rationale as the how talk of of against we'll in past, And will there of this about to that course, we so is of I discussed the progress to really were ESMO some been within dose course. the we're give go the that dual

Operator

Your Oppenheimer. next the is Hartaj Singh from question with of line

Hartaj Singh

Great, thank update. you, for Eliot the and everyone

Would you're cohorts for couple expanding the and for just a of year, Eliot, the to I you with initial of that sort strategy first have them you be stratified continue any signal patients will Assuming change going And sort this FSXXX, a going thoughts you with the the doing how with any half of or DLBCL and FSXXX? it cancer acquired clinical of more have next give this recruit trial that? a secondly, on question. is lung quarter that first in a readout, us Just regular resistance does and the forward strategy in then with Thanks to trial that? would expect of cell your year? Just where next on of looking sort One then patients you just to data with trial then around where contours strategy? non-small Phase be questions. good new would

Eliot Forster

know look of are to will population, with come the a So the much lymphoma respect biomarker at I design within that cell give about set again, of got specific little cancer patients the the believe Clearly, this the a those the B-cell protocol to in But us - that naïve of We non-small and expansion patient we around best checkpoint lung bit strategy repeat response. course both cohorts this this. I year. can't reveal will into we've too that later there the stage.

to to With think very than checkpoint we as different have versus balance. therapy design chemotherapy, had had type after an know, respect I then are a to response quality acquired and go is disease both prospect to resistance a they areas all you decision going we looking and in we're the who you'd West, duration about better of order to throwing in at These that resistance, sure plus we all when for the points of approach I expect and go probably us the with types population, patients then life with in are two a is become really and the need refractory. you're do. And adaptive excited the tend believe where But acquired weren't also least palliation have where make be basket once. those at sensible, early to format. two through eggs certainly we accelerate of into we there our our settings And advantage an of them. in

that now is will first towards next in So position with be there in and is monitor emerged in we to would just population we be the recent the in as internal ambition two a the And the would discussions expand We've a the guess checkpoint progress data. non-clinical data need play to our a looked of settings but to run out what hopefully, we enthusiasm, we've we've clearly, important, subject that feel is And really regulators, that naïve we resistance on a would as And continued naïve. diminish clinical year checkpoint I word the ASCO what our of into genuine setting. our think alighted well. doesn't half data acquired in upon parallel registration. rapid for to opportunity conference. this rapidly hope to always hope out medical it those nor

Hartaj Singh

data follow-up, that Great, to have Eliot or for other you from XXX that you. And months? you into there or giving you the XXX insights are the over quick transactional types Thanks to any get tumor insights thank six just for are then into additional question? could data XX look next third-party

Eliot Forster

thanks again Sure, Hartaj.

where FSXXX. increasing say With any a to progress We're of - will molecules. look with think watch stage our in wait we'll that about we FSXXX just both other need clinical progress before what's And ESMO about. I we going with in trial updated those So with more XXX, can hands. very of give excited programs the for on the interest

our continue because PD-LX believe We real molecule setting. of low XXX is that to for the opportunity in the

for of we think I the opportunity watch ratios even unique And that sit many continue externally achieved. enthusiasm opening - that setting here cancer with to see the who targets, have same we we the what's what as that and we we've up. in I and we've targeting to my seen PD-LX remarks some tuning patients, CDXXX with have again for those PD-LX given doesn't XXX doing seen of have low molecules don't to today, what we've other diminish here mentioned options. internally, think we coming But the a well

Operator

line & the with is Jen next of Yale Your from question Company. Laidlaw

Yale Jen

And thanks questions. taking the for

not of XXX and even Regarding a some greater - rate, readouts, cell that the survival cancer, the superior in which free progression that particularly chemotherapy trials. during the and/or non-small which in-patients the noticed the our are is than and PD-X the we checkpoint response lung patients

you that shot have question? a to aspect So will feel are than better another you these have them, I improve think some combination do the follow-up

Eliot Forster

exhaustion Obviously, LAG-X of patients. of that's established terms melanoma, the data at Sure, so that in in it's we important. that BMS think the mechanistically I base kind checkpoint very but look in set now LAG-X/PD-LX hypothesis, in co-simultaneous very, important in believe our aside pathway the the treated is if emerging been we inhibition,

that I would And we of T be prevent from LAG-X certainly a so would in exhaustion kind as were, checkpoint question, think I if of those pathway, exhausted have underlying even extended PFS be the better of hope the that that inhibitor it. surface and/or the would guess one, it initiating probably the I hope would - to because macro we your was is would that create hypothesis yes addresses and the direction cleaved thinking. cells that

Yale Jen

Yes, absolutely other that's level you that again you or very any terminal point one, that choose provide do patient, of and color to helpful. and into or is two Maybe the at in new thanks? want know this security follow-up measure checkpoint so patients – - discount PD-LX patients or

Eliot Forster

that with to have afraid. that thanks question. you I'm disappoint I'm to Yes, for going one same

Nice We about details at of try, we'll will stage. a though the speak Thanks. the details. about the speak design later trial

Operator

is H.C. Wainwright. Your with Patrick line the of question Trucchio next from

Patrick Trucchio

XXXXX. SB on ups follow couple a Just

XXXXX forward to you Phase then would patients or beyond you X? would collaboration to what be look partner? Phase to your dose you the ongoing thirdly, if potential First SB to is dose can and develop development. an And to if including escalation of I'm move give own have you XXXX, as would And confidence X look how for the wondering you and would discuss doses? generated the looking forward so, which part on efficacy, a in which update the and you And further data inform to-date update on secondly,

Eliot Forster

is additional what the And so we of is I us the generating pharmacology there They about. to obvious if a to the the we a to or of some of The that. expect I safety But culture beyond have that maybe give were enable interesting confidence XXXXX have few And announced halves talked a that it it? tolerated and certainly enough that uptake. fulfilling clinical therefore weeks seen well a confidence give PK and And characteristics of generating benefit, we bit PD-LX. that couple kind should interested combination There's cellular safe signs targeted is with we level. is press a announced in. half some haven't announced us achieved early disease, by we'll clear of continue - with is, of we update in the already reached keep the tolerability. mono we're a immune the beginning with in with with pharma that stabilization levels of ago We've PD-X And of that cell of certainly other we'd and I and that signs two seen and protocol to doses drug correspond as XXXXX agonist. that's on we've escalation kind called cellular doses that going. benefit other in clinical first to we'll think and targeted kind beyond five mono-therapy and next So the three-combination We which thing that. either of the is said, year is the kind uptake, add STING seeing markers Tecentriq think of of also second from way of generation we've is couple is done to is, doses. drug that, give a the us give the confidence it as And that had a

safety really those already second as and you clinical as we can those so with profile, where we molecule, our what - not to With box. It's the certainly would sit we or carrying X it. a well it some through well strategic as ourselves, Phase the the characteristics cool tetravalent seeking STING two, signs all check it's were, think as so bispecific plus were know, tolerated elements, give excited get of generation it collaborations to is it's as classic And and And efficacy, today, so open here it a in platform. include with into now that. will we're beyond minded respect be we it, partnerships but it's but and from to respect exploring possibilities. that we portfolio, I it to as do that intravenously, with all the I our, two And way phase forward we're said, not

it taken generation for collaborate be molecule, the that to molecules is we'd - although to sorts make so of And these patients' forwards sure. happy benefit right that's sure a fits under We second want to get circumstances.

Patrick Trucchio

wondering Yes. and next data FSXXX with this expectations the I'm can then programs? later readouts FSXXX for us on in those you expected And readouts just for the your the steps frame year, if

Eliot Forster

that I mentioned trial quite so of the it I some we'll minor because or year see get did for be with beyond, the will that some the in nonetheless, those Keytruda questions looking we beyond sort sort guidance Not as we'll one address, effect. trigger steps nice non-clinically, with mono-therapy well, we really that the hanging or two combination, to combination, of program. to course, but other to actually next mono-therapy be same an league to also of that But a although half month’s development to combination and Sure, instance. continue effects. ESMO, as as And looking think study into FSXXX be first some biology started, progress in give of the give will the will tolerability as in next of update first at slightly update

those explore should we so And well. as probably

and XXX, continue response to targeting as it's expansion, to into expressing much and tumors, in confident think dose I we those be PK Phase and end again we of I of be I PD-LX clinical fourth certainly said, X an in ascending For and at earlier the study. We'll of an that dose quarter, that data reasonably provide into clinical question can low We'll as We'll biological safety in well talk a any give about that. update stage. at on we part stage. that tolerability to the and able anticipate be course, have study advanced data we'll to and would by that data ascending any monotherapy pharmacology,

Patrick Trucchio

that? $XXX you the the just or that development give milestones any of then cadence AstraZeneca milestones if you us details or on if of the versus idea can us million an commercial what couldn't, collaboration, And one can you on give and proportion

Eliot Forster

what is answer. you thing I the unfortunate was and give only press in so the release then Yes, Patrick a can generic

and that term, let upfront million near milestones. term $XXX development in So million repeat just least commercialization USDXX near and at me so

a will pharma. without would much giving say, between biotech to away, you it think a that see that is structured a and most it's I too be deal deals fair like

So I all would steps of that, you give afraid. or the around you of orders that clinic I'm development in but see magnitude beyond, and the contour can't really any

Operator

Riley next Your from the of question is Walsh B. with Securities. Justin line

Justin Walsh

Thanks for taking questions. the

with Nature you whether wondering any I The have or that's publication, had discussions in testing the combination therapy, first about XXXXX if based? one, was potentially given radiopharmaceutical radiation external guys Communications if

Eliot Forster

as so, even interesting, synergies really But a on with it. will accommodation, we through and agonist, have Tecentriq, development may which it PD-LX to XXXXX that's PD-LX. main our for the done microenvironment in And clinical keep a of or it us, on on in affecting the we see an it piece to time collaboration We're undertake intriguing with that to this us, Look, intrigued be is all an would for of with the research. was opened you partner, to to be there. profile respect how be combination focus the interesting data has focus Russia's very and radiations there going were certainly our tumor be immune to focused emergence that certainly by the new be something got if eye of But either our thinking. right where know some and with now, it combination stage in And got at it XXXXX

Justin Walsh

second also my is question XXXXX. And on

in they in express guys really just it bit are that the that bringing and great further agonist for is any of those things Did came the So, interest side little forward that a inhibitors. STING you of licensed it's types or topics? AstraZeneca

Eliot Forster

data We've step really the so the mentioned just program next because group a But we've the earlier level Yes, of particular we I limited is expanding XXX seen. as working dose we're narrowed the the of ourselves to through to conversation AZ program option inhibitors. was inhibitors. to the the The conversation to work. by

be within inhibitors of really used interesting, but not in We not As the diseases our were. so And as cancer, know, our do it and expertise. to you on. expertise. an are inflammatory that's It's area

Operator

call showing are time, no to over At turn further that would this back there like questions, to I the [Operator Instructions] Elliot. I'm

Eliot Forster

had you'd quarter. corporate you much. agree to morning. hope we've for clinical thank very continued us this Well, our And strategies. on productive joining we've thanks, a I deliver And everyone and

expansion we period. the huge believe over the three other there's clinical course, of FSXXX, With our potential. And of programs well stage progress

that, truly milestones partnership of and to mission over investors, the patients healthcare non-core clinic, highlight AstraZeneca months. next and We the of updating of runway our to our clinical the I'd the all With deliver again trials. show And goodbye. of another very continue marked again. much planned you And we're track professionals we dedication contribute thank bring that, thank all unwavering new more daily course, to In transform have in to XX to to a with lives existing who and who work our cancer. collaboration our assets. you with to on patients in all will to to the the that and cash market for And look new colleagues and like medicines will the with strong forward our labs fall. clinical many F-star particular, the strategy from you the progress

Operator

We and you your lines. gentlemen Thank you for ask call. that participating disconnect today's in ladies now conference

F-star Therapeutics (FSTX) 12 Aug 212021 Q2 Earnings call transcript